<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260912071016N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-09-20</date_registration>
      <primary_sponsor>Zahedan University of Medical Sciences</primary_sponsor>
      <public_title>Comparing the Effectiveness of Sleeve Gastrectomy and Gastric Bypass in Weight Loss and Control of Diabetes and High Blood Pressure in People with Obesity</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the Efficacy of Sleeve Gastrectomy and Gastric Bypass in Weight Loss and Control of Comorbidities (Diabetes and Hypertension) in Obese Patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>102</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>https://irct.ir/trial/93215</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Health service research, Randomization description: In this study, randomization will be performed using block randomization with a fixed block size of 4 and an allocation ratio of 1:1, at the individual level, without stratification. The random sequence will be generated using R/SPSS software or a random number table and then placed in opaque, sealed, and numbered envelopes.

Participants will be entered into the pre-generated random sequence as follows: eligible patients, after confirmation of inclusion and exclusion criteria, provision of informed consent, and collection of baseline data, will be enrolled consecutively in the order of presentation. For each patient, an independent person will open the next numbered envelope, and the allocated group—sleeve gastrectomy or gastric bypass—will be determined according to the contents of that envelope. In this way, the pre-generated random sequence will be followed sequentially, without influence from the patient or the clinical investigator.

If central randomization is used, the independent person will contact the randomization center, and the allocation for the next patient will be announced in a concealed manner. Allocation concealment will be performed using sealed envelopes or central randomization by an independent person.

It should be noted that allocation concealment and blinding are two distinct processes. Allocation concealment occurs before the patient’s group is revealed, in order to reduce bias in enrollment; blinding, however, is applied after allocation during the intervention or outcome assessment. In this study, blinding of patients and surgeons is not feasible, but the outcome assessor and data analyst will be blinded, Blinding description: Accordingly, blinding will be as follows: patients and surgeons will not be blinded because the type of surgery is evident to the patient and the surgical team. The outcome assessor will be blinded to the allocated group and will not know whether patients were assigned to sleeve gastrectomy or gastric bypass at the time of outcome assessment. The data analyst will also be blinded, and group codes will remain unknown until analysis is complete. Allocation concealment before surgery will be performed using opaque, sealed, and numbered envelopes or central randomization by an independent person, so that the next patient’s allocation remains concealed until enrollment. This design is described as an open-label trial with a blinded outcome assessor and a blinded data analyst.</study_design>
      <phase>3</phase>
      <hc_freetext>Obesity, Type 2 Diabetes Mellitus (T2DM), and Hypertension (High Blood Pressure).</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Laparoscopic sleeve gastrectomy; longitudinal removal of 75–80% of the stomach with linear stapler and 36–40 Fr bougie; Veress entry, 4–5 trocars, ultrasonic energy; operative time 60–90 min, hospital stay 1–2 days. Diet/supplement education and follow-up at 1, 3, 6, and 12 months. Intervention 2: Control group: Laparoscopic Roux-en-Y gastric bypass; 25–30 mL gastric pouch with linear stapler and 18-mm bougie; small bowel divided at the ligament of Treitz; gastrojejunostomy and jejunojejunostomy; operative time 90–120 min, hospital stay 2–3 days. Same follow-up as intervention group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
de-identified individual participant data (age, sex, baseline BMI, surgery type, weight, HbA1c, blood pressure, complications) for the primary outcome and diabetes/hypertension control; the full de-identified dataset is potentially shareable, though public access is usually limited to primary outcome and key comorbidity variables.

When:
It will be one year after the implementation of the project.

To whom:
University students and researchers

Conditions:
Purpose: The data/documents may be used only for academic, non-commercial research, reproducibility, meta-analyses, and evaluating sleeve gastrectomy vs. gastric bypass effects on weight loss and diabetes/hypertension control in obese patients.

Where to obtain:
Please refer to Dr. Hamid Hakimi, Department of Surgery, Ali Ibn Abi Talib Hospital, Zahedan, or contact him by email at dr.hakimi@zaums.ac.ir.

How to obtain:
A data/document request begins with a formal request to the study lead/ethics committee, is reviewed by the data access committee, and upon approval, a data-sharing agreement is signed and de-identified data are delivered.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hamid Hakimi Nia</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>University Campus of Medical Sciences.,Doctor Hesabi Square</address>
        <city>Zahedan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9816743463</zip>
        <telephone>+98 54 3329 5570</telephone>
        <email>dr.hakimi@zaums.ac.ir</email>
        <affiliation>Zahedan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hamid Hakimi Nia</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>niversity Campus of Medical Sciences,Doctor Hesabi Square</address>
        <city>Zahedan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9816743463</zip>
        <telephone>+98 54 3329 5570</telephone>
        <email>dr.hakimi@zaums.ac.ir</email>
        <affiliation>Zahedan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age: 18 to 65 years
Body mass index equal to or greater than 40 kilograms per square meter; or Body mass index equal to or greater than 35 kilograms per square meter accompanied by at least one obesity-related comorbidity.
Comorbidities (at least one of the following):    Type 2 diabetes (especially poorly controlled despite medical therapy)    Hypertension (especially resistant to medical therapy)
History of unsuccessful weight loss: failure to achieve sustained weight loss with non-surgical methods (diet, exercise, medication) under medical supervision
Psychological clearance: mental health assessment and approval by a qualified specialist
Willingness for long-term follow-up: commitment to regular and lifelong follow-up after surgery</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of prior major abdominal surgery (other than bariatric surgery) that may have altered anatomy and makes either procedure unpredictable.
Uncontrolled psychiatric disorder or inability to understand and adhere to postoperative instructions, impairing the ability to follow dietary regimens and long-term follow-up.
Active substance or alcohol abuse that significantly increases the risk of postoperative complications and non-adherence to the diet.
Severe and uncontrolled comorbidities (e.g., heart failure, liver failure, or advanced renal failure) that make surgical risk unacceptable.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E66.813</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Obesity Class 3</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Laparoscopic sleeve gastrectomy; longitudinal removal of 75–80% of the stomach with linear stapler and 36–40 Fr bougie; Veress entry, 4–5 trocars, ultrasonic energy; operative time 60–90 min, hospital stay 1–2 days. Diet/supplement education and follow-up at 1, 3, 6, and 12 months.</i_keyword>
      <i_keyword>Control group: Laparoscopic Roux-en-Y gastric bypass; 25–30 mL gastric pouch with linear stapler and 18-mm bougie; small bowel divided at the ligament of Treitz; gastrojejunostomy and jejunojejunostomy; operative time 90–120 min, hospital stay 2–3 days. Same follow-up as intervention group.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Body mass index. Timepoint: Time points for body mass index measurement: baseline (before surgery) and 1, 3, 6, and 12 months after surgery. Method of measurement: dividing body weight in kilograms by the square of height in meters.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Glycated hemoglobin. Timepoint: baseline (before surgery) and 1, 3, 6, and 12 months after surgery. Method of measurement: Method of measuring glycated hemoglobin: measurement using a high-performance liquid chromatography analyzer and a standard glycated hemoglobin kit.</sec_outcome>
      <sec_outcome>Hypertension control. Timepoint: baseline (before surgery) and 1, 3, 6, and 12 months after surgery. Method of measurement: using a calibrated mercury sphygmomanometer with a stethoscope.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Zahedan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-05-10</approval_date>
        <contact_name>Zahedan University of Medical Sciences Ethics Committee</contact_name>
        <contact_address>Medical Sciences Campus, Dr. Hesabi Square, Zahedan, Sistan and Baluchistan Province,  Iran. Zahedan Sistan-va-Balouchestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
